Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early simplification to Trizivir in virologically suppressed HIV patients on Combivir + Kaletra
2004-002296-16Phase 4Active
- Sponsor
- Antonio Antela López
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of abacavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Antonio Antela López. Primary endpoints: Virological response at 48 weeks after simplification to Trizivir and Safety and tolerability at 48 weeks after simplification to Trizivir. Started May 2005; status: active.
02
Drugs
abacavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2004-002296-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002296-16.